Liquid Biopsy
A liquid biopsy project with
Canexia Health
ACTT Project - Access to Cancer Testing & Treatment in Response to COVID-19
Access to the ctDNA test FOLLOW IT Liquid Biopsy
Update – July 13 2022
Canexia Health will continue to provide Follow It testing under Project ACTT at no cost until September 31st for breast cancer and December 31st for lung cancer.
- The liquid biopsy test is available for lung and breast cancer.
Patients with colorectal cancers will be able to access Canexia Health’s tests on a patient-pay basis. Please contact Canexia Health directly regarding this option at info@canexiahealth.com
Announced on July 15, 2020, the ACTT Project is a consortium led by Vancouver-based Canexia Health (formerly Contextual Genomics), which provides cancer patients (metastatic or relapse of breast, colorectal or non-small cell lung cancers) with access to tests and treatment options during the COVID-19 pandemic.
Supported by the Digital Technology Supercluster, the ACTT Project will deploy and enhance a liquid biopsy solution that requires only a simple blood draw that can help oncologists guide the choice of cancer treatment and clinical trial options for their patients, eliminating the need for many patients to go to the hospital for surgical biopsies.
The ACTT Project will enable 2,000 Canadian patients (from Quebec, Ontario, Saskatchewan and British Columbia) to access the FOLLOW IT test at no cost, through March 31, 2021, whereas the cost of using this test is usually paid by the patient.
FOLLOW IT is a liquid biopsy test using next-generation sequencing to detect mutations in circulating tumor DNA (ctDNA) in the blood.
Genolife is proud to be Canexia Health’s partner and to provide access to this project in Quebec.
Test Requisition for ctDNA test : FOLLOW ITTM Liquid Biopsy